NEW YORK – With a recent round of $1 million in funding, digital health care company QuiO is preparing to launch the market’s first smart injector, the Si One.
The Si One is capable of administering any type of syringe-based medication, automating the entire injection process, from needle insertion to drug delivery to needle retraction. The needle is hidden inside the device, so the patient doesn’t have to see it go in and out.
“It’s no small feat to perform a self-injection, and when you add in a patient’s fear of needles, you have serious adherence issues,” said Alexander Dahmani, co-founder and CEO of QuiO. “That’s why we believe the Si One will be a game-changer for patients, their loved ones and their care teams.”
The Si One also records how much medication is in the syringe and how much was actually injected, transmitting that information to the company’s cloud platform in real-time. Automated texts and phone calls are delivered to the patient and/or caregiver if something goes wrong with the injection or if an injection is missed.
Dahmani believes the Si One is a game-changer because there is no home injection monitoring solution on the market.
“We offer a seamless solution that doesn’t require any syncing, smartphone or mobile app to work,” he said. “Another advantage we have over competitors is our proprietary design that enables health care organizations to deploy our device off-the-shelf across multiple injection therapies.”
The Si One will impact the home health care space by providing a solution that prevents mistakes and allows monitoring for therapies already self-injected at home, Dahmani said. He said the device will also help therapies that are administered in clinics, such as IV drugs, move to the home.
QuiO has received some interest in the device from home health agencies, Dahmani said, and he believes it can help them save money.
“Instead of in-person visits for administering an injectable therapy and recording each closing event, they can remotely monitor the regimen with our technology,” he said.
Dahmani said that while the company readies the Si One for market next year, QuiO is already developing a second smart injector device, the Si Pen, which is designed for insulin cartridges.